{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:51:20Z","timestamp":1793757080133,"version":"4.6.1"},"reference-count":82,"publisher":"Journal of Biological Methods","issue":"1","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HPR"],"abstract":"<jats:p>Purpose of Review\nThis is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia.\nRecent Findings\nSchizophrenia is a chronic mental health disorder that affects approximately 3.3 million people in the United States. Its symptoms, which must be present more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication.Lumateperone is a selective and concurrent modulator of serotonin, dopamine, and glutamate, which all mediate or modulate serious mental illness.\nSummary\nSchizophrenia is a complex, severe mental illness that affects how the brain processes information. There are many medications used to treat schizophrenia. One antipsychotic agent, lumateperone tosylate, is a newer agent that the FDA recently approved. The most common adverse effects are shown to be mild such as somnolence, constipation, sedation, and fatigue, with the 42 mg recommended dose. Lumateperone tosylate is an FDA-approved drug that can be given only at the 42mg dose once daily with no titration requirements.<\/jats:p>","DOI":"10.52965\/001c.24932","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:47:53Z","timestamp":1624621673000},"page":"1","source":"Crossref","is-referenced-by-count":17,"title":["Lumateperone tosylate, A Selective and Concurrent Modulator of \u00a0Serotonin, Dopamine, and Glutamate, in the Treatment of \u00a0Schizophrenia\u00a0"],"prefix":"10.14440","volume":"9","author":[{"given":"Kunal","family":"Maini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"W. Hollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Bollich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"LaForge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"M. Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"N. Edinof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"M. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"D. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5574","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/archgenpsychiatry.2012.652","article-title":"From perception to functional outcome in schizophrenia: Modeling the role of ability and motivation","volume":"69","author":"Michael F. Green","year":"2012","journal-title":"Archives of General Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14728214.2020.1773792","article-title":"Emerging 5-HT receptor antagonists for the treatment of Schizophrenia","volume":"25","author":"Mackenzie T. Jones","year":"2020","journal-title":"Expert Opinion on Emerging Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1744-7623","issn-type":"print"},{"issue":"11","key":"ref3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient","volume":"50","author":"Shitij Kapur","year":"2001","journal-title":"Biological Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"issue":"12","key":"ref4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Jeffrey A Lieberman","year":"2005","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/00325481.2019.1701823","article-title":"New discoveries for an old drug: a review of recent olanzapine research","volume":"132","author":"Amir M. Meftah","year":"2020","journal-title":"Postgraduate Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1941-9260","issn-type":"print"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/schbul\/sbx066","article-title":"A Transdiagnostic Review of Negative Symptom Phenomenology and Etiology","volume":"43","author":"Gregory P. Strauss","year":"2017","journal-title":"Schizophrenia Bulletin","ISSN":"https:\/\/id.crossref.org\/issn\/1745-1701","issn-type":"print"},{"issue":"2","key":"ref7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14656566.2019.1695778","article-title":"An evaluation of lumateperone tosylate for the treatment of schizophrenia","volume":"21","author":"Pankhuri Vyas","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/1465-6566","issn-type":"print"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/NDT.S157475","article-title":"Novel treatment options in depression and psychosis","volume":"14","author":"Eva Ceskova","year":"2018","journal-title":"Neuropsychiatric Disease and Treatment","ISSN":"https:\/\/id.crossref.org\/issn\/1178-2021","issn-type":"print"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: A concise overview of incidence, prevalence, and mortality","volume":"30","author":"John McGrath","year":"2008","journal-title":"Epidemiologic Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/0193-936X","issn-type":"print"},{"key":"ref10","article-title":"Epidemiology and risk factors of schizophrenia","journal-title":"PubMed"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Ren\u00e9 S. Kahn","year":"2015","journal-title":"Nature Reviews Disease Primers","ISSN":"https:\/\/id.crossref.org\/issn\/2056-676X","issn-type":"print"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: A reexamination","volume":"62","author":"Brian A. Palmer","year":"2005","journal-title":"Archives of General Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"6614","key":"ref13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/bmj.296.6614.63","article-title":"Is schizophrenia a neurodevelopmental disorder?","volume":"296","author":"R. M Murray","year":"1988","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia - An Overview","volume":"77","author":"Robert A. McCutcheon","year":"2020","journal-title":"JAMA Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/2168-622X","issn-type":"print"},{"issue":"2-3","key":"ref15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.schres.2004.08.022","article-title":"Dermatoglyphics and Schizophrenia: A meta-analysis and investigation of the impact of obstetric complications upon a\u2013b ridge count","volume":"75","author":"Elvira Bramon","year":"2005","journal-title":"Schizophrenia Research","ISSN":"https:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bmb\/ldh046","article-title":"Predictors of schizophrenia - A review","volume":"73-74","author":"Pirjo M\u00e4ki","year":"2005","journal-title":"British Medical Bulletin","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1420","issn-type":"print"},{"issue":"7","key":"ref17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1176\/appi.ajp.159.7.1080","article-title":"Obstetric complications and schizophrenia: Historical and meta-analytic review","volume":"159","author":"Mary Cannon","year":"2002","journal-title":"American Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"NOV.","key":"ref18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1192\/bjp.181.5.387","article-title":"Adult psychosis, common childhood infections and neurological soft signs in a national birth cohort","volume":"181","author":"Stuart J. Leask","year":"2002","journal-title":"British Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1250","issn-type":"print"},{"issue":"7","key":"ref19","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.pnpbp.2011.07.002","article-title":"Winter birth excess in schizophrenia and in non-schizophrenic psychosis: Sex and birth-cohort differences","volume":"35","author":"Jos\u00e9 M. Mart\u00ednez-Ortega","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0278-5846","issn-type":"print"},{"issue":"3","key":"ref20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/oxfordjournals.schbul.a007030","article-title":"A Systematic Review and Meta-analysis of Northern Hemisphere Season of Birth Studies in Schizophrenia","volume":"29","author":"Geoffrey Davies","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"9","key":"ref21","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1176\/appi.ajp.159.9.1528","article-title":"Paternal age and risk of schizophrenia in adult offspring","volume":"159","author":"Alan S. Brown","year":"2002","journal-title":"American Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"8","key":"ref22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.comppsych.2012.05.009","article-title":"Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia","volume":"53","author":"Gregory P. Strauss","year":"2012","journal-title":"Comprehensive Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0010-440X","issn-type":"print"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/archpsyc.58.4.361","article-title":"Advancing paternal age and the risk of schizophrenia","volume":"58","author":"Dolores Malaspina","year":"2001","journal-title":"Archives of General Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"3","key":"ref24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.psc.2007.04.007","article-title":"Epidemiology of Schizophrenia: Review of Findings and Myths","volume":"30","author":"Erick L. Messias","year":"2007","journal-title":"Psychiatric Clinics of North America","ISSN":"https:\/\/id.crossref.org\/issn\/0193-953X","issn-type":"print"},{"issue":"7474","key":"ref25","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/bmj.38243.672396.55","article-title":"Paternal age and schizophrenia: A population based cohort study","volume":"329","author":"Attila Sipos","year":"2004","journal-title":"British Medical Journal","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8146","issn-type":"print"},{"issue":"1","key":"ref26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/schbul\/sbl053","article-title":"Environment and schizophrenia: Environmental factors in schizophrenia: Childhood trauma - A critical review","volume":"33","author":"Craig Morgan","year":"2007","journal-title":"Schizophrenia Bulletin","ISSN":"https:\/\/id.crossref.org\/issn\/0586-7614","issn-type":"print"},{"issue":"4","key":"ref27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.chc.2013.04.006","article-title":"Childhood Trauma and Psychosis","volume":"22","author":"Yael Dvir","year":"2013","journal-title":"Child and Adolescent Psychiatric Clinics of North America","ISSN":"https:\/\/id.crossref.org\/issn\/1056-4993","issn-type":"print"},{"issue":"7374","key":"ref28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/bmj.325.7374.1199","article-title":"Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study","volume":"325","author":"Stanley Zammit","year":"2002","journal-title":"British Medical Journal","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8146","issn-type":"print"},{"issue":"2","key":"ref29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1586\/14737175.1.2.183","article-title":"Risk factors for schizophrenia","volume":"1","author":"Jane Boydell","year":"2001","journal-title":"Expert Review of Neurotherapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/1473-7175","issn-type":"print"},{"issue":"7","key":"ref30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ajmg.b.32177","article-title":"What can we learn about schizophrenia from studying the human model, drug-induced psychosis?","volume":"162","author":"Robin M. Murray","year":"2013","journal-title":"American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/1552-4841","issn-type":"print"},{"issue":"12","key":"ref31","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","article-title":"Schizophrenia as a Complex Trait: Evidence from a Meta-analysis of Twin Studies","volume":"60","author":"Patrick F. Sullivan","year":"2003","journal-title":"Archives of General Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Keith H. Nuechterlein","year":"2004","journal-title":"Schizophrenia Research","ISSN":"https:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.mp.4001232","article-title":"Chromosomal abnormalities and mental illness","volume":"8","author":"D. J. MacIntyre","year":"2003","journal-title":"Molecular Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1359-4184","issn-type":"print"},{"issue":"2","key":"ref34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1086\/321969","article-title":"Schizophrenia and affective disorders - Cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: Clinical and P300 findings in a family","volume":"69","author":"D. H.R. Blackwood","year":"2001","journal-title":"American Journal of Human Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9297","issn-type":"print"},{"issue":"2","key":"ref35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11920-008-0026-1","article-title":"Schizophrenia and 22q11.2 deletion syndrome","volume":"10","author":"Anne S. Bassett","year":"2008","journal-title":"Current Psychiatry Reports","ISSN":"https:\/\/id.crossref.org\/issn\/1523-3812","issn-type":"print"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2017.00322","article-title":"Genetics of schizophrenia: Overview of methods, findings and limitations","volume":"11","author":"Mads G. Henriksen","year":"2017","journal-title":"Frontiers in Human Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/1662-5161","issn-type":"print"},{"issue":"4","key":"ref37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41380-018-0041-5","article-title":"Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures","volume":"24","author":"Emanuele Felice Osimo","year":"2019","journal-title":"Molecular Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1359-4184","issn-type":"print"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.conb.2013.11.003","article-title":"Inhibitory neurons in human cortical circuits: Substrate for cognitive dysfunction in schizophrenia","volume":"26","author":"David A. Lewis","year":"2014","journal-title":"Current Opinion in Neurobiology","ISSN":"https:\/\/id.crossref.org\/issn\/0959-4388","issn-type":"print"},{"issue":"4","key":"ref39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/mp.2013.30","article-title":"Altered gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia","volume":"19","author":"A. L. Guillozet-Bongaarts","year":"2014","journal-title":"Molecular Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1476-5578","issn-type":"print"},{"issue":"12","key":"ref40","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/mp.2013.165","article-title":"Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain","volume":"19","author":"S. S. Kaalund","year":"2014","journal-title":"Molecular Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1476-5578","issn-type":"print"},{"issue":"2-3","key":"ref41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.psychres.2012.02.018","article-title":"Negative symptoms in individuals at clinical high risk of psychosis","volume":"196","author":"Danijela Piskulic","year":"2012","journal-title":"Psychiatry Research","ISSN":"https:\/\/id.crossref.org\/issn\/0165-1781","issn-type":"print"},{"issue":"2","key":"ref42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0006-8993(79)90349-4","article-title":"Synaptic density in human frontal cortex - Developmental changes and effects of aging","volume":"163","author":"Huttenlocher Peter R.","year":"1979","journal-title":"Brain Research","ISSN":"https:\/\/id.crossref.org\/issn\/0006-8993","issn-type":"print"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0920-9964(97)00043-1","article-title":"Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia","volume":"26","author":"Helene L. Provencher","year":"1997","journal-title":"Schizophrenia Research","ISSN":"https:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"4","key":"ref44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0022-3956(82)90038-3","article-title":"Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?","volume":"17","author":"I. Feinberg","year":"1982","journal-title":"Journal of Psychiatric Research","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3956","issn-type":"print"},{"issue":"6","key":"ref45","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/schbul\/sbr134","article-title":"Neuroanatomical maps of psychosis onset: Voxel-wise meta-analysis of antipsychotic-naive vbm studies","volume":"38","author":"Paolo Fusar-Poli","year":"2012","journal-title":"Schizophrenia Bulletin","ISSN":"https:\/\/id.crossref.org\/issn\/0586-7614","issn-type":"print"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.cub.2016.04.035","article-title":"Spatial Working Memory in Humans Depends on Theta and High Gamma Synchronization in the Prefrontal Cortex Article Spatial Working Memory in Humans Depends on Theta and High Gamma Synchronization in the Prefrontal Cortex","volume":"26","author":"Ivan Alekseichuk","year":"2016","journal-title":"Current Biology"},{"issue":"2","key":"ref47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrn2774","article-title":"Abnormal neural oscillations and synchrony in schizophrenia","volume":"11","author":"Peter J. Uhlhaas","year":"2010","journal-title":"Nature Reviews Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/1471-003X","issn-type":"print"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2017.08.063","article-title":"Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [11C]PBR28 study","volume":"195","author":"Sudhakar Selvaraj","year":"2018","journal-title":"Schizophrenia Research","ISSN":"https:\/\/id.crossref.org\/issn\/1573-2509","issn-type":"print"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Sudhakar Selvaraj","year":"2014","journal-title":"Neuroscience and Biobehavioral Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1873-7528","issn-type":"print"},{"issue":"1-3","key":"ref50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.schres.2016.04.037","article-title":"Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank","volume":"177","author":"Brian Dean","year":"2016","journal-title":"Schizophrenia Research","ISSN":"https:\/\/id.crossref.org\/issn\/1573-2509","issn-type":"print"},{"issue":"1","key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1471-4159.2003.01693.x","article-title":"The cortical serotonin2A receptor and the pathology of schizophrenia: A likely accomplice","volume":"85","author":"Brian Dean","year":"2003","journal-title":"Journal of Neurochemistry","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3042","issn-type":"print"},{"issue":"S7","key":"ref52","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.5694\/j.1326-5377.2007.tb01335.x","article-title":"Clinical staging: a heuristic model for psychiatry and youth mental health","volume":"187","author":"Patrick D McGorry","year":"2007","journal-title":"Medical Journal of Australia","ISSN":"https:\/\/id.crossref.org\/issn\/0025-729X","issn-type":"print"},{"issue":"8","key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"Piotr St\u0119pnicki","year":"2018","journal-title":"Molecules","ISSN":"https:\/\/id.crossref.org\/issn\/1420-3049","issn-type":"print"},{"issue":"10","key":"ref54","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","article-title":"Schizophrenia is a cognitive illness: Time for a change in focus","volume":"70","author":"Ren\u00e9 S. Kahn","year":"2013","journal-title":"JAMA Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/2168-622X","issn-type":"print"},{"issue":"4238","key":"ref55","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Ian Creese","year":"1976","journal-title":"Science","ISSN":"https:\/\/id.crossref.org\/issn\/0036-8075","issn-type":"print"},{"issue":"2","key":"ref56","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action","volume":"25","author":"Shitij Kapur","year":"2000","journal-title":"Journal of Psychiatry and Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/1180-4882","issn-type":"print"},{"issue":"7","key":"ref57","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated with Classical Neuroleptics and Clozapine: Relation to Extrapyramidal Side Effects","volume":"49","author":"Lars Farde","year":"1992","journal-title":"Archives of General Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1538-3636","issn-type":"print"},{"issue":"4","key":"ref58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients","volume":"33","author":"Anna Lena Nordstr\u00f6m","year":"1993","journal-title":"Biological Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"issue":"12","key":"ref59","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"S Miyamoto","year":"2012","journal-title":"Molecular Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1359-4184","issn-type":"print"},{"key":"ref60","isbn-type":"print","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/7854_2010_47","article-title":"Antipsychotic drug development","volume":"4","author":"Dennis H. Kim","year":"2010","ISBN":"https:\/\/id.crossref.org\/isbn\/9783642137167","journal-title":"Current Topics in Behavioral Neurosciences","ISSN":"https:\/\/id.crossref.org\/issn\/1866-3389","issn-type":"print"},{"issue":"10","key":"ref61","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.3390\/ijms19103105","article-title":"Multi-target approach for drug discovery against schizophrenia","volume":"19","author":"Magda Kondej","year":"2018","journal-title":"International Journal of Molecular Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/1422-0067","issn-type":"print"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuropharm.2013.10.021","article-title":"Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action","volume":"79","author":"Giuseppe Mocci","year":"2014","journal-title":"Neuropharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3908","issn-type":"print"},{"issue":"29","key":"ref63","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future","volume":"16","author":"Peng Li","year":"2016","journal-title":"Current Topics in Medicinal Chemistry","ISSN":"https:\/\/id.crossref.org\/issn\/1568-0266","issn-type":"print"},{"issue":"1","key":"ref64","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.","volume":"251","author":"H. Y. Meltzer","year":"1989","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"APR. SUPPL. 23","key":"ref65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1192\/s0007125000292714","article-title":"The epidemiology of early schizophrenia. Influence of age and gender on onset and early course","volume":"164","author":"H. Hafner","year":"1994","journal-title":"British Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1250","issn-type":"print"},{"issue":"1","key":"ref66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"S Miyamoto","year":"2005","journal-title":"Molecular Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1359-4184","issn-type":"print"},{"issue":"6","key":"ref67","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Robert E. Davis","year":"2016","journal-title":"Expert Review of Neurotherapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/1473-7175","issn-type":"print"},{"issue":"4","key":"ref68","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial","volume":"77","author":"Christoph U. Correll","year":"2020","journal-title":"JAMA Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/2168-622X","issn-type":"print"},{"issue":"4","key":"ref69","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: First Approval","volume":"80","author":"Hannah A. Blair","year":"2020","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1179-1950","issn-type":"print"},{"key":"ref70","article-title":"Lumateperone Drug Prescribing and Safety Information","author":"FDA Label"},{"issue":"3","key":"ref71","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia","volume":"44","author":"Kimberly E. Vanover","year":"2019","journal-title":"Neuropsychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1740-634X","issn-type":"print"},{"issue":"4","key":"ref72","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamapsychiatry.2019.4265","article-title":"The Potential Role of Lumateperone - Something Borrowed? Something New?","volume":"77","author":"Joshua T. Kantrowitz","year":"2020","journal-title":"JAMA Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/2168-622X","issn-type":"print"},{"issue":"9","key":"ref73","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","author":"Filippo Corponi","year":"2019","journal-title":"European Neuropsychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1873-7862","issn-type":"print"},{"issue":"3","key":"ref74","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Gretchen L. Snyder","year":"2015","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1432-2072","issn-type":"print"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"106002802093659","DOI":"10.1177\/1060028020936597","article-title":"Lumateperone: A Novel Antipsychotic for Schizophrenia","author":"Jessica Greenwood","year":"2020","journal-title":"Annals of Pharmacotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/1060-0280","issn-type":"print"},{"issue":"5","key":"ref76","doi-asserted-by":"publisher","first-page":"0413","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Sukanta Saha","year":"2005","journal-title":"PLoS Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1549-1277","issn-type":"print"},{"issue":"12","key":"ref77","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial","volume":"79","author":"Jeffrey A. Lieberman","year":"2016","journal-title":"Biological Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1873-2402","issn-type":"print"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"S453","DOI":"10.1016\/j.euroneuro.2019.09.642","article-title":"P.671 Efficacy and safety of lumateperone tosylate 42mg in the treatment of schizophrenia: A pooled analysis of phase 2 and 3 studies","volume":"29","author":"J.M. Kane","year":"2019","journal-title":"European Neuropsychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"2","key":"ref79","first-page":"33","article-title":"Lumateperone for schizophrenia","volume":"19","author":"Jonathan M. Meyer","year":"2020","journal-title":"Current Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1537-8276","issn-type":"print"},{"issue":"1","key":"ref80","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess Early Mortality in Schizophrenia","volume":"10","author":"Thomas Munk Laursen","year":"2014","journal-title":"Annual Review of Clinical Psychology","ISSN":"https:\/\/id.crossref.org\/issn\/1548-5943","issn-type":"print"},{"issue":"10","key":"ref81","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.4088\/JCP.13049tx5c","article-title":"Assessing disability in schizophrenia: tools and contributors","volume":"75","author":"Philip D. Harvey","year":"2014","journal-title":"The Journal of clinical psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1555-2101","issn-type":"print"},{"issue":"1-3","key":"ref82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \"Just the Facts\" What we know in 2008. 2. Epidemiology and etiology","volume":"102","author":"Rajiv Tandon","year":"2008","journal-title":"Schizophrenia Research","ISSN":"https:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"}],"container-title":["Health Psychology Research"],"original-title":[],"link":[{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/20250408124356517b09511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/20250408124356517b09511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T03:50:29Z","timestamp":1760413829000},"score":1,"resource":{"primary":{"URL":"https:\/\/healthpr.org\/journal\/HPR\/9\/1\/10.52965\/001c.24932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,7,18]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.24932","relation":{},"ISSN":["2420-8124"],"issn-type":[{"value":"2420-8124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]}}}